Pharvaris N.V.

NASDAQ:PHVS

Biotechnology

Healthcare
$31.55 -1.93%

-$0.64 today

Market cap
$2.21B
Beta
-2.33
P/E (TTM)
-11.0
EPS (TTM)
-$2.59
52W Low $16.72High $34.41

Volume 0.39M

Average 0.31M

PHVS Net Income

Bottom-line profit after all expenses, interest, and taxes.

Pharvaris N.V.NASDAQ: PHVS

Net Income · Q3 FY2026 · quarter ended Sep 2026

Net income remains negative

Q3 FY2026 net income was -€47.41M, compared with -€37.14M a year earlier. Trailing-twelve-month net income was -€181.84M.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 10 analysts of -€159.88M (+9.0%) for the fiscal year ending Dec 2026, a step up from the -30.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-€47.41M+0.9% QoQ
Last fiscal yearDec 2025
-€175.7M-30.9% YoY
LTMSep 2026
-€181.84M-9.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.7%-0.9%+26.7 pp
1 year-30.9%+9.0%+39.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the income statement

Latest · FY2025
(175.7M) EUR
Year-over-year change
-30.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How PHVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.5% is the 3rd highest of 7, against a peer median of -60.7%.
PHVS Competitors
Net Income for PHVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PHARPharming Group N.V.LTM Mar 2026$12.33M USD+187.5%-40.6%3.3%
RLYBRallybio CorporationLTM Mar 2026-$7.82M USD+83.8%—911.1%
TVTXTravere Therapeutics, Inc.LTM Sep 2026-$121.51M USD-37.2%—18.7%
PHVSPharvaris N.V.LTM Sep 2026-€181.84M EUR-9.5%——
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026-$384.67M USD-977.2%—40.9%
VERAVera Therapeutics, Inc.LTM Jun 2026-$401.9M USD-84.1%——
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-$122.73B USD-23682.5%+35.1%11.9%
Peer median (excluding PHVS) —-60.7%-2.8%18.7%

Competitors are the stored peer set for PHVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development35.79M57.38M65.58M98.56M124.48M
Selling, General & Admin18.35M29.34M31.34M47.12M45.34M
Operating Expenses54.14M86.71M96.91M145.69M169.82M
Depreciation & Amortization77.37K152.94K257.55K269.56K418.35K
EBITDA(42.31M)(86.56M)(99.57M)(145.42M)(173.29M)
EBITDA Margin—————
Operating Income(54.14M)(86.71M)(96.91M)(145.69M)(169.82M)
Operating Margin—————
Interest Income2681605.47M0
Interest Expense278.18K16.11K000
Other Income / Expenses11.48M11.06M(2.91M)13.29M(3.89M)
Income Before Tax(42.66M)(75.65M)(99.83M)(132.4M)(173.71M)
Pre-Tax Margin—————
Income Tax Expense70.12K679.09K1.05M1.83M1.99M
Net Income(42.73M)(76.33M)(100.88M)(134.22M)(175.7M)
Net Margin—————
EPS (Basic)(1.41)(2.27)(2.63)(2.48)(2.97)
EPS (Diluted)(1.41)(2.27)(2.63)(2.48)(2.97)
Weighted Avg Shares30.41M33.59M38.39M54.02M59.16M
Weighted Avg Shares (Diluted)30.41M33.59M38.39M54.02M59.16M

Pharvaris N.V.

NASDAQ:PHVS

Intrinsic Alpha fair value

Locked

Current Price

$31.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.